FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1242-1244 April 19, 2001 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The use of estrogen-replacement therapy has been associated with a lower risk of Alzheimer's disease¹ and preserved or enhanced cognitive performance in postmenopausal women.² Despite the consistency of these observations, there are lingering doubts surrounding the observational studies of estrogen use. The failure to measure factors such as differences in the health-seeking behavior or socioeconomic status of women who choose to use or not to use estrogen has been an important limitation. It has therefore become important to conduct well-designed, controlled clinical trials of estrogen-replacement therapy for the treatment or prevention of cognitive impairment and dementia. More recently, selective estrogen-receptor . . . [Full Text of this Article]

References

This article has been cited by other articles:

• (2001). Does Raloxifene Affect Cognitive Function in Postmenopausal Women?. JWatch Neurology 2001: 5-5 [Full Text]